Antibody Discovery and Development Against Non-Immunogenic Snake Venom Toxins

Snake venom contains small toxins that the human immune system barely notices, so current antivenoms often fail to stop them. This matters because snakebites kill and disable tens of thousands of people each year, mostly in rural tropical regions. The toxins that cause the worst damage—bleeding, paralysis, tissue destruction—are often the smallest molecules in the venom. They slip past the immune response, so antibodies raised in horses or sheep (the standard way to make antivenom) rarely bind them effectively. The result: patients receive treatment that neutralises some venom components but leaves the most dangerous ones untouched. The researchers plan to outsmart this problem. They will design synthetic versions of these small toxins that the immune system *can* recognise, then use those to generate antibodies in the lab. They will also screen vast libraries of artificial antibodies to find ones that latch onto the real toxins with high precision. If this works, the antibodies could be added to existing antivenoms or developed into standalone treatments. The impact would be felt in rural clinics across Asia, Africa, and Latin America, where snakebite is a daily occupational hazard for farmers and herders. Better neutralisation of these hidden toxins could mean fewer amputations, less paralysis, and more people walking out of hospital alive.